

Allegra Battistoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2010022/publications.pdf>

Version: 2024-02-01

52
papers

722
citations

566801

15
h-index

610482

24
g-index

53
all docs

53
docs citations

53
times ranked

1174
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. <i>International Journal of Cardiology</i> , 2012, 157, 160-168.	0.8	76
2	NPR-C: a component of the natriuretic peptide family with implications in human diseases. <i>Journal of Molecular Medicine</i> , 2010, 88, 889-897.	1.7	61
3	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 381-388.	1.0	43
4	Calcium Channel Blockers and Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 121-130.	1.0	40
5	Prevalence and clinical outcomes of whiteâ€œcoat and masked hypertension: Analysis of a large ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 297-305.	1.0	36
6	Association Between Lifestyle and Systemic Arterial Hypertension in Young Adults: A National, Survey-Based, Cross-Sectional Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 31-40.	1.0	28
7	Might reninâ€œangiotensin system blockers play a role in the COVID-19 pandemic?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 248-251.	1.4	28
8	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2092.	1.8	25
9	Natriuretic peptides in heart failure: Current achievements and future perspectives. <i>International Journal of Cardiology</i> , 2019, 281, 186-189.	0.8	23
10	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 1-8.	1.0	22
11	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. <i>Hypertension</i> , 2020, 76, 1753-1761.	1.3	19
12	Vascular Aging and Central Aortic Blood Pressure: From Pathophysiology to Treatment. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 299-308.	1.0	19
13	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	0.8	19
14	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. <i>Clinical Cardiology</i> , 2015, 38, 387-394.	0.7	18
15	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 327-341.	1.0	18
16	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. <i>International Journal of Cardiology</i> , 2017, 248, 342-348.	0.8	15
17	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	0.8	15
18	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , 2019, 124, 972-974.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 373-377.	1.0	14
20	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , 2021, 12, 652163.	1.3	14
21	A Novel Electrocardiographic Tâ€Wave Measurement (Tpâ€Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for Firstâ€Line Electrocardiographic Evaluation. <i>Journal of Clinical Hypertension</i> , 2015, 17, 441-449.	1.0	13
22	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. <i>International Journal of Cardiology</i> , 2020, 321, 150-154.	0.8	12
23	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 353-63.	0.7	11
24	Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. <i>International Journal of Cardiology</i> , 2022, 349, 134-137.	0.8	11
25	Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment. <i>European Journal of Heart Failure</i> , 2016, 18, 442-444.	2.9	10
26	Hypertension in the elderly: which are the blood pressure threshold values?. <i>European Heart Journal Supplements</i> , 2019, 21, B105-B106.	0.0	10
27	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. <i>Clinical Cardiology</i> , 2018, 41, 788-796.	0.7	9
28	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 85.	1.5	9
29	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339.	1.0	8
30	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020, 38, 1005-1015.	0.3	8
31	Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?. <i>European Cardiology Review</i> , 2020, 15, e21.	0.7	8
32	Integrated Preclinical Cardiovascular Prevention: A New Paradigm to Face Growing Challenges of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 163-170.	1.0	6
33	Hypertension Across the Atlantic: A Sprint or a Marathon?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 99-102.	1.0	6
34	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24â€hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 967-975.	1.0	6
35	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 243-253.	1.0	5
36	Antihypertensive drugs and the risks of cancer: More fakes than facts. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1323-1326.	0.8	5

#	ARTICLE	IF	CITATIONS
37	NT-proANP/ANP is a Determinant of Vascular Damage in Humans. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 117-120.	1.0	4
38	New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. Medical Sciences (Basel), 2020, 13, 1046-1048.	1.3	4
39	Angiotensin II-Linked Hypothesis to Understand the Advantage of the Coevolution of Hypertension and Malaria. Circulation Research, 2016, 119, 1046-1048.	2.0	3
40	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 255-263.	1.0	3
41	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 467-473.	1.0	3
42	An evolutionary rebus. Journal of Hypertension, 2019, 37, 1344-1346.	0.3	3
43	The "hidden side of the moon" in hypertension: When and why is dangerous low diastolic blood pressure?. International Journal of Cardiology, 2019, 276, 268-270.	0.8	2
44	Genes and hypertension: stepping into the secret through the arterial wall. European Heart Journal, 2020, 41, 3323-3324.	1.0	2
45	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 195-201.	1.0	2
46	Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. Journal of Hypertension, 2021, 39, 169-180.	0.3	2
47	Shooting beyond score. Journal of Hypertension, 2012, 30, 1909-1910.	0.3	1
48	Lifestyle and cardiovascular disease: Barefooting through the guidelines. International Journal of Cardiology, 2018, 263, 156-157.	0.8	1
49	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 255-262.	1.0	1
50	Repurposing Cardio-Metabolic Drugs to Fight Covid19. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 419-423.	1.0	1
51	What's HIV got to do with cardiovascular disease?. International Journal of Cardiology, 2018, 265, 210-211.	0.8	0
52	Diastolic Blood Pressure Levels and Cardiovascular Risk in Elderly Women: The Need for a Personalized Approach. American Journal of Hypertension, 0, , .	1.0	0